Andrew Natenshon

Andrew Natenshon is currently the VP, Program Executive, Infectious Disease at Moderna Therapeutics. Andrew has over 15 years of experience in the field of vaccines and has worked with some of the biggest names in the industry. Prior to their current position, they were the Senior Director Clinical Program Lead at Genocea Biosciences, responsible for leading a multi-function team through the clinical development of a novel T-cell based vaccine for HSV-2. Andrew has also held positions at Seqirus and Novartis Vaccines, where they were responsible for oversight of vaccine development and product management for commerical vaccines. In addition to their work in the private sector, Andrew has also served as an Advisor for the Bill and Melinda Gates Foundation and as a Senior Associate at McKinsey and Company.

After completing their high school education at Deerfield Academy, Andrew Natenshon attended Dartmouth College, where they earned an AB in Chemistry. Andrew then pursued a career in international health and economics, earning an MA from The Johns Hopkins University. Andrew later earned another MA from The Johns Hopkins University - Paul H. Nitze School of Advanced International Studies (SAIS), in the field of international econ and international health.

Andrew Natenshon reports to Stephen Hoge, President. Some of their coworkers include Rose Loughlin - VP, R&D Strategy, Jacqueline Miller - SVP, Therapeutic Area Head, Infectious Diseases.